An Unusual Case of Baclofen Abuse

Das, Soumitra; Palappalllil, Dhanya Sasidharan; Purushothaman, Sumesh Thoppil; Rajan, Varun

doi:10.4103/0253-7176.191383

Cited by 10 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…57 Further studies have demonstrated GABA B 's role in the reward process, and this offers a plausible explanation for why these GABA B agonists elicit similar addiction profiles. 58 Though this clarifies the sedative nature of GHB, it offers little explanation for its excitatory effects, let alone its natural role in the CNS. It was not until the discovery of a GHB-specific receptor in 1982 that GHB's concentration-dependent nature was fully understood.…”

Section: Acs Chemical Neurosciencementioning

confidence: 99%

“…This idea is supported by the reportedly similar addictive nature of baclofen, given that both substances act as GABA B agonists, though baclofen does so selectively . Further studies have demonstrated GABA B ’s role in the reward process, and this offers a plausible explanation for why these GABA B agonists elicit similar addiction profiles . Though this clarifies the sedative nature of GHB, it offers little explanation for its excitatory effects, let alone its natural role in the CNS.…”

Section: Behavioral and Molecular Pharmacologymentioning

confidence: 99%

See 1 more Smart Citation

DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)

Trombley

Capstick

Lindsley

2019

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Gamma-hydroxybutyrate (GHB) is a naturally occurring short-chain fatty acid that rose to prominence as a popular club drug in the 1990s. Originally developed as an anesthetic in the early 1960s, it was later sold as an over-the-counter dietary supplement before becoming a rising substance of abuse in the following decades as one of the “date rape” drugs. Despite its abuse potential, there has been a recent surge in therapeutic interest in the drug due to its clinical viability in the treatment of narcolepsy and alcohol abuse/withdrawal. Its interactions with the GABAergic framework of higher mammals has made it the prototypical example for the study of the chief inhibitory mechanism in the human central nervous system. Though relatively obscure in terms of popular culture, it has a storied history with widespread usage in therapeutic, recreational (“Chemsex”), and some disturbingly nefarious contexts. This Review aims to capture its legacy through review of the history, synthesis, pharmacology, drug metabolism, and societal impact of this DARK classic in chemical neuroscience.

show abstract

Section: Acs Chemical Neurosciencementioning

confidence: 99%

Section: Behavioral and Molecular Pharmacologymentioning

confidence: 99%

DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)

Trombley

Capstick

Lindsley

2019

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…In a case study from India by Das et al . 8) a 24-year-old male abused baclofen up to 600 mg/day with euphorient effects.…”

Section: To the Editormentioning

confidence: 99%

Abuse Liability of Baclofen

Praharaj

2018

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

“…While an important consideration, once a drug is labeled as having potential abuse liability, its consideration as a possible treatment option is often dismissed by clinical practitioners. For example, because of their varying degrees of possible abuse liability, gabapentin [ 6 , 7 ], pregabalin [ 8 ], baclofen [ 9 , 10 ], and bupropion [ 11 ] may not be routinely used generally by some practitioners when treating SUDs, despite the frequent use of these agents in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders

et al. 2022

View full text Add to dashboard Cite

Purpose of Review This review summarizes recent clinical trial research on pharmacological treatments for substance use disorders, with a specific focus on agents with potential abuse liability. Recent Findings Pharmacological treatments for substance use disorders may include gabapentinoids, baclofen, modafinil, ketamine, cannabinoids, gamma-hydroxybutyrate, and psychedelics. Gabapentinoids may decrease negative subjective effects of withdrawal in alcohol and cannabis use disorders. Cannabinoids similarly appear to decrease use and withdrawal symptoms in cannabis use disorder, while research shows stimulant medications may reduce cravings and increase abstinence in cocaine use disorder. Ketamine and psychedelics may help treat multiple substance use disorders. Ketamine may reduce withdrawal symptoms, promote abstinence, and diminish cravings in alcohol and cocaine use disorders and psychedelics may promote remission, decrease use, and reduce cravings in alcohol and opioid use disorders. Summary Regardless of current regulatory approval statuses and potentials for abuse, multiple agents should not be dismissed prematurely as possible treatments for substance use disorders. However, further clinical research is needed before effective implementation can begin in practice. Supplementary Information The online version contains supplementary material available at 10.1007/s40429-022-00432-9.

show abstract

An Unusual Case of Baclofen Abuse

Cited by 10 publications

References 11 publications

DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)

DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)

Abuse Liability of Baclofen

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders

Contact Info

Product

Resources

About